|
Idera Pharmaceuticals, Inc. - Comparative Business Analysis Snapshot
Business Description
Idera Pharmaceuticals, Inc.. The Company's principal activity is discovering and developing novel therapeutics that modulate immune responses through Toll-like Receptors (TLR). TLRs are specific receptors present in immune system cells that direct the immune system to respond to potential disease threats. The Company discovers and develops synthetic DNA- and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies and for use as vaccine adjuvants. It has three internal programs, in oncology, infectious diseases, and autoimmune diseases and two collaborative alliances relating to the development of treatments for asthma and allergies and the development of adjuvants for vaccines. The Company is currently conducting a Phase 2 trial of IMO-2055 in oncology and a Phase 1/2 trial of IMO-2055 in combination with chemotherapy in oncology. Its trademarks are IMOtm, Idera(R), IMOxine(R) and GEM(R). The Company operates in the United States.
Competitor Analysis
This analysis compares Idera Pharmaceuticals, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
